Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy
- Orally administered treatment was well tolerated, with early signs of clinical activity
- In models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal capillary loss and vascular leakage
- Data support continued advancement into Phase 2 clinical evaluation
Copenhagen, Denmark, 24 June 2025 – Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology focused biopharmaceutical company developing oral therapeutics for the early treatment of vascular eye diseases, today announces the successful completion of its Phase 1b clinical trial evaluating its lead candidate, danegaptide, in patients with non-proliferative diabetic retinopathy (NPDR) with associated edema.
